Aardvark Therapeutics files for IPO. Company develops hunger-targeting obesity drug ARD-101 and ARD-201, led by CEO Tien Lee.

UnitedHealth Group has named a new CEO to lead its health insurance business, following the murder of the division’s former ...

We’re in the first week of the second Trump administration, and it’s becoming clearer how it might impact healthcare ...

Anthos Therapeutics' abelacimab shows lower bleeding risk vs Xarelto in atrial fibrillation trial, with 62% reduction in ...

Purdue Pharma and the Sackler family have agreed to a $7.4 billion settlement in a longstanding legal battle over the nation’s opioid epidemic.

What will President Donald Trump's team do on healthcare? Nobody knows for sure. That was the general agreement among the policy experts who advise the drug industry last week at the JP Morgan ...

Teva, Astellas and AstraZeneca say they will participate in the next round of Medicare negotiations under the Inflation Reduction Act, even though they continue to criticize the process as “price ...

Not many biotechs survive beyond 25 years, let alone get multiple drugs approved and turn a profit. BioMarin Pharmaceutical has done all that, but finds itself navigating ...

FDA delays Stealth BioTherapeutics' elamipretide decision to April 29; Valneva's Ixchiq succeeds in child safety trial; TargetRx raises $50M; Ab&B Bio-Tech files for HKEX IPO ...

Quantum Health laid off 4% of workforce shortly after naming Dayne Williams as CEO. The company serves 3M+ members for ...

Catalent to make Galapagos' CAR-T therapy, Kindeva gets $129M DuoDote contract, Solarbiotech/GPC Bio/Eleszto merge, Afrigen ...

Xilio's vilastobart plus Roche's Tecentriq shows partial responses in colorectal cancer trial, but company faces cash ...